Metagenomi Therapeutics Inc. reported FY 2025 results, ending the year with USD 160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025, and said its runway is anticipated to support operations through Q4 2027. For FY 2025, the company reported collaboration revenue of USD 25.2 million, R&D expenses of USD 94.4 million, G&A expenses of USD 26.8 million, loss from operations of USD 96.0 million, and net loss of USD 87.9 million (net loss per share of USD 2.36). On business updates, Metagenomi said it completed a pre-IND meeting for MGX-001 (hemophilia A) following preclinical data showing curative FVIII activity in non-human primates, and remains on track for a global regulatory submission including an IND in Q4 2026, with clinical trials planned to start in 2027 subject to regulatory clearance. The company also reported in vivo proof-of-concept in non-human primates for antithrombin (AT-III) deficiency, and highlighted preclinical data supporting APOC3 as a collaboration target with Ionis Pharmaceuticals. Metagenomi also announced a corporate name change to Metagenomi Therapeutics, Inc. to reflect its strategic evolution.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metagenomi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603051605PRIMZONEFULLFEED9666805) on March 05, 2026, and is solely responsible for the information contained therein.
Comments